Researcher

Zeliha Birsin

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 9, 2026 · JOURNAL ARTICLE

Association of PET/CT-Derived Metabolic Parameters with Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: An Analysis Across Molecular Subtypes

Diagnostics

Retrospective single-center study of moderate size showing PET/CT parameters independently predict pathological complete response with improved model discrimination, but lacks prospective validation and external generalization.

PromisingMehmet Taner Bodur Ebru Çiçek Zeliha Birsin

Reported

Sample size162

AUC (ΔPrimary Tumor SUVmax model)0.837

AUC (post-treatment primary tumor…0.848

SEP 8, 2026 · JOURNAL ARTICLE

Progression Patterns as Determinants of Post-Progression Survival in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors

Cerrahpasa Medical Journal

Retrospective single-center study of 87 patients identifying progression patterns as prognostic factors for post-progression survival in CDK4/6-inhibitor-treated HR+/HER2− metastatic breast cancer, with statistically significant hazard ratios for visceral and liver progression but limited by design and sample size.

PromisingNebi Serkan Demirci Murat Günaltılı Zeliha Birsin

Reported

Sample size87

New visceral progression prevalen…56.3%

New liver metastases prevalence35.6%